Delayed
NSE India S.E.
11:42:58 2025-02-06 pm EST
5-day change
1st Jan Change
1,005.55 INR
-0.26%
+3.76%
+3.60%
Nomura Upgrades Zydus Lifesciences to Buy From Neutral, Adjusts Price Target to INR1,140 From INR1,030
January 10, 2025 at 02:01 am EST
This article is reserved for members
Not a member ?
Free registration
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,350 From INR1,380, Keeps at Buy
Feb. 06
MT
Zydus Lifesciences Posts Rise in Fiscal Q3 Consolidated Net Profit
Feb. 05
MT
Zydus Lifesciences Limited, Q3 2025 Earnings Call, Feb 05, 2025
Feb. 05
India's Zydus Life beats profit view on strong US demand
Feb. 05
RE
Zydus Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024
Feb. 05
CI
Weight Loss Drug Semaglutide Launch in India to Mainly Benefit Larger Players, Jefferies Says
Jan. 30
MT
Zydus Lifesciences Limited Receives Demand Order-In-Original for the Tax Period from July 2017 to March 2021
Jan. 25
CI
Zydus Lifesciences' Usnoflast Gets Orphan Drug Designation Status from US FDA
Jan. 22
MT
Zydus Lifesciences Gets USFDA Nod for Phase II(b) Trial of Usnoflast in ALS
Jan. 20
MT
Zydus Lifesciences Receives Approval from USFDA to Conduct Phase II(B) Clinical Trial for Usnoflast
Jan. 18
CI
Nomura Upgrades Zydus Lifesciences to Buy From Neutral, Adjusts Price Target to INR1,140 From INR1,030
Jan. 10
MT
CVS Health Unit to Include Zydus Lifesciences' Diabetes Medications in Template Formulary
Jan. 07
MT
Zydus Announces Agreement with CVS Caremark to Add Zituvio Tm, Zituvimettm and Zituvimettm XR (Sitagliptin | Sitagliptin and Metformin Hydrochloride) to Its Template Formulary
Jan. 06
CI
Zydus Lifesciences Limited Appoints Vikram Shukla as a President-Parenteral Operations
Jan. 03
CI
Zydus Lifesciences Gets Final Approval from US FDA for Lidocaine and Prilocaine Cream
Dec. 19
MT
Zydus Lifesciences Limited Receives Final Approval from USFDA for Lidocaine and Prilocaine Cream USP, 2.5%/2.5%
Dec. 19
CI
Zydus Lifesciences Limited Receives Demand Order-In-Original from Assistant Commissioner, Division Dehradun, Sector-7, Uttarakhand
Nov. 28
CI
Nomura Adjusts Zydus Lifesciences' Price Target to INR1,030 From INR1,020, Keeps at Neutral
Nov. 14
MT
Jefferies Adjusts Zydus Lifesciences' Price Target to INR1,380 From INR1,450, Keeps at Buy
Nov. 13
MT
Zydus Lifesciences Posts Gains in Fiscal Q2 Consolidated Net Profit
Nov. 13
MT
Zydus Lifesciences Limited, Q2 2025 Earnings Call, Nov 12, 2024
Nov. 12
India's Zydus Life posts Q2 profit rise on steady US demand
Nov. 12
RE
Zydus Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024
Nov. 12
CI
Zydus Lifesciences Limited Receives in Principle Acceptability from World Health Organization for Zyvac Tcv
24-10-23
CI
Zydus Lifesciences Limited Receives Final Approval from USFDA for Fludrocortisone Acetate Tablets USP, 0.1 Mg
24-10-17
CI
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
More about the company
Last Close Price
1,008.20 INR
Average target price
1,069.45 INR
Spread / Average Target
+6.08%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1